FLSM
Frazier Life Sciences Management Portfolio holdings
AUM
$2.5B
This Quarter Return
+13.35%
1 Year Return
+52.94%
3 Year Return
+530.54%
5 Year Return
–
10 Year Return
–
AUM
$2.41B
AUM Growth
+$2.41B
(-3.4%)
Cap. Flow
-$42.5M
Cap. Flow
% of AUM
-1.77%
Top 10 Holdings %
Top 10 Hldgs %
66.5%
Holding
55
New
2
Increased
13
Reduced
9
Closed
5
Top Buys
| 1 |
NewAmsterdam Pharma
NAMS
|
$78.7M |
| 2 |
Pliant Therapeutics
PLRX
|
$14.8M |
| 3 |
Trevi Therapeutics
TRVI
|
$13.5M |
| 4 |
KalVista Pharmaceuticals
KALV
|
$10.2M |
| 5 |
PVLA
Palvella Therapeutics, Inc. Common Stock
PVLA
|
$7.66M |
Top Sells
| 1 |
Edgewise Therapeutics
EWTX
|
$41.7M |
| 2 |
Krystal Biotech
KRYS
|
$31.3M |
| 3 |
Rhythm Pharmaceuticals
RYTM
|
$30.6M |
| 4 |
Vaxcyte
PCVX
|
$27.8M |
| 5 |
Tyra Biosciences
TYRA
|
$17.2M |
Sector Composition
| 1 | Healthcare | 99.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Aclaris Therapeutics
ACRS
$223M
| – | – |
-264,377
| Closed | -$304K |
|
52
Nuvation Bio
NUVB
$1.08B
| – | – |
-1,218,236
| Closed | -$2.79M |
|
53
Puma Biotechnology
PBYI
$258M
| – | – |
-3,062,558
| Closed | -$7.81M |
|
54
PepGen
PEPG
$39M
| – | – |
-702,694
| Closed | -$6.01M |
|
|
55
Tyra Biosciences
TYRA
$657M
| – | – |
-731,020
| Closed | -$17.2M |
|